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Aims To examine the independent prognostic role of functional mitral regurgitation (FMR) and its impact across the sever-
ity of chronic heart failure (CHF) in a large population of outpatients with systolic CHF followed at two multidisci-
plinary clinics.
Methods
and results
Echocardiography was performed upon enrolment in 469 CHF patients. Follow-up for death and heart transplant was
updated on January 2007. Five-year transplant-free survival was 82.7% in patients with no or Grade I FMR, 64.4% in
Grade II, 58.5% in Grade III, and 46.5% in Grade IV (P, 0.0001). There was a strong graded association between FMR
and the long-term risk of death and heart transplant, which remained significant after multivariable adjustment
(P ¼ 0.0003). The association between FMR and events was strong and independent in patients with less severe
symptoms and in those at lower overall risk based on a propensity score analysis, while it was not significant in
patients with more advanced CHF or in the high-risk subgroup (P, 0.0001 for interactions).
Conclusion This study clarifies previous apparently discrepant results by demonstrating that FMR is an independent determinant
of death and heart transplantation only in less severe CHF and in patients with a lower risk profile. This finding indi-
cates that FMR plays a major role in the early phase of CHF, suggesting that this should be the focus of strategies
attempting to reduce it.
- - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - -
Keywords Heart failure † Functional mitral regurgitation † NHYA class † Death † Heart transplantation
Introduction
Functional mitral regurgitation (FMR), due to left ventricular and
annular dysfunction in the absence of organic lesions, is frequent
in patients with chronic heart failure (CHF).1 Although some pre-
vious studies observed that even mild FMR is associated with a
dismal outcome,2–6 others did not find an independent associ-
ation7 especially in more advanced CHF patients.8 These discre-
pancies are yet to be reconciled and currently result in major
prognostic and therapeutic uncertainties.
Furthermore, no available study has systematically examined the
role of FMR across the whole spectrum of CHF and among
patients managed at dedicated multidisciplinary outpatient clinics,
where patients are uniformly followed by a dedicated team accord-
ing to the most updated guidelines.8
The aim of the present study was to examine the independent
prognostic role of FMR and to evaluate its impact across the
severity of CHF in a large population of outpatients with CHF
and systolic left ventricular (LV) dysfunction followed at two
multidisciplinary CHF outpatient clinics.
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Methods
Heart failure clinics
We enrolled patients from the CHF outpatient clinics of Modena and
Bologna University Hospitals in Italy. These CHF clinics are multidisci-
plinary outpatient clinics, which treat and manage patients with CHF.
Dedicated CHF clinics have been shown to enhance patient compli-
ance and physician adherence to evidence-based therapies and
current guidelines.9–11
Patient population
Between July 1997 and September 2006, 546 patients with clinical
diagnosis of CHF were prospectively enrolled at the dedicated out-
patient clinics of Modena and Bologna University Hospitals. Upon
enrolment, all patients underwent transthoracic echocardiography
and the clinical and echocardiographic data were immediately
entered onto electronic databases at both clinics. We retro-
spectively examined and merged the databases of these two CHF
clinics.
Patients with systolic dysfunction (ejection fraction ,50%) at enrol-
ment were included. Exclusion criteria were organic mitral regurgita-
tion (mitral valve prolapse, rheumatic disease, endocarditis, previous
papillary muscle rupture, or abnormalities in mitral valve leaflets or
chordae), mitral and aortic valve prosthesis, previous mitral valve
repair, and congenital heart disease. FMR was assessed and graded in
469 subjects and these patients constitute the study population. Of
these, 289 (61.6%) patients were enrolled at the CHF clinic in
Modena and 180 (38.4%) in Bologna.
Patient characteristics
Upon enrolment in the CHF clinics, all patients underwent clinical
and physical examination, including the clinical assessment of
New York Heart Association (NYHA) functional class based on
the symptoms reported by the patient; assessment of the main
aetiology of CHF (ischaemic aetiology was defined as significant cor-
onary artery disease on angiography in the presence of a history of
myocardial infarction or Q waves on the ECG);4 and comorbidities
(chronic obstructive pulmonary disease, chronic kidney disease,
hypertension or use of antihypertensive medications, and diabetes
mellitus).12
During the baseline visit the patients underwent a12-lead ECG to
assess cardiac rhythm and presence of Q waves.
Doppler echocardiographic examination
Atrial and ventricular diameters were assessed by M-mode in line with
the recommendations of the American Society of Echocardiography.13
FMR was measured semiquantitatively, assessing the regurgitant jet
area by colour Doppler.14 FMR measured with this method has
been shown to be associated with outcomes in patients after myocar-
dial infarction.2 FMR was classified as either absent or as one of the
four progressive degrees of severity from mild to more severe mitral
regurgitation (Grade I through Grade IV). Two observers blindly
reviewed the echocardiographic images which were stored on DVD
and blindly assigned the grading. The inter-observer variability
between the two operators in grading MR was assessed in 20 randomly
selected patients. The correlation coefficient was 0.96 (95% CI: 0.89–
0.98), P, 0.0001.
LV ejection fraction was assessed by the biplane Simpson method or
the Quinones method using the LV end-systolic and end-diastolic
diameters15 or visually estimated, a method that was documented to
have an accuracy comparable with the other methods in assessing
LV ejection fraction.16
Follow-up
The main outcome variable was death or heart transplantation. At the
CHF clinics, patients are followed-up on a regular basis according to
the severity of symptoms and disease. Follow-up and therapy are con-
sistently optimized for each patient. The patients from both clinics are
referred to the same regional centre for heart transplant, therefore
information about heart transplantation was available for all patients
and eligibility criteria were homogeneous.
Follow-up for death was 100% complete and was obtained from the
national death database. Patients were followed until death, heart
transplant, or January 2007. Patients who moved out of the region
before the outcome were censored as alive. Death was classified as
cardiac, non-cardiac, or unknown. Among patients who died from
cardiac causes, we identified those who died from sudden cardiac
death. Autopsy records and death certificates were consulted for attri-
bution of the cause of death.
Statistical analysis
Data are presented as percentages or mean+ SD, unless otherwise
specified. Severely skewed variables are presented as median (25th–
75th percentile). Only 5.3% of patients had no FMR and their charac-
teristics and outcome were similar to patients with a lesser degree of
FMR (Grade I), hence for the purpose of the analyses and for display
purposes, these two groups were combined. Therefore, the study
population was categorized into 4 groups: patients with no FMR or
Grade I FMR, Grade II FMR, Grade III FMR, and Grade IV FMR. Com-
parisons across groups were performed by x2 test for categorical vari-
ables and analysis of variance (ANOVA) for continuous variables, and
the P-value for trend is shown. Kaplan–Meier curves were constructed
to display survival-free from heart transplant. Univariate and multivari-
able Cox regression analysis were performed to assess the unadjusted
and adjusted hazard ratio (HR) and 95% confidence intervals (CI) for
the risk of death or heart transplant during the follow-up. Patients
were censored at the time of death, heart transplant, or last follow-up.
Since some patients underwent coronary bypass or mitral valve
surgery during the long follow-up, which may have influenced the
degree of FMR and its effect on survival, we subsequently assessed
outcome under non-surgical management. We censored the patients
at death or heart transplant, while censoring them alive if they under-
went subsequent coronary bypass or mitral valve surgery or at last
follow-up if they did not undergo surgery.
To identify the subgroup at highest risk, we used propensity score
analysis; a logistic regression model was performed to calculate the
predicted probability of death or heart transplant by incorporating
the following variables in this multivariable model: age, sex, NYHA
class, ischaemic aetiology, atrial fibrillation, chronic kidney disease,
renal failure, chronic obstructive pulmonary disease, angiotensin con-
verting enzyme (ACE) inhibitors/angiotensin receptor blocker (ARB),
beta-blockers, implantable cardioverter defibrillator (ICD), cardiac
resynchronization therapy, and LV ejection fraction. We then identified
the patients in the highest quartile of the distribution of the variable
resulting from the predicted probability model and we classified
these patients as highest risk. We tested for multiple interaction
models by adding to the multivariable Cox regression analysis the
interaction terms (FMR*ischaemic aetiology, FMR*NYHA class, and
FMR*higher risk patients). Then, we performed stratified analyses to
assess the association between FMR and outcome by CHF severity
and by risk profile.
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Results
Population
Of the 469 patients enrolled, 313 (66.7%) were men, the mean age
was 59.6+13.3 (range 21–90) years, and the underlying aetiology
of CHF was ischaemic in 170 patients (36.2%). At enrolment, 45
patients (9.6%) were in NYHA functional Class I, 271 (57.8%) in
Class II, 142 (30.3%) in Class III, and 11 (2.3%) in Class IV. Mean
LV ejection fraction was 29.7+ 7.9%.
Functional mitral regurgitation and
baseline characteristics
FMR was absent in 25 (5.3%) patients; it was Grade I in 151
(32.2%), Grade II in 87 (18.6%), Grade III in 142 (30.3%), and
Grade IV in 67 (13.6%) subjects.
Patients with a worse degree of FMR were more likely to have a
higher NYHA class, worse LV ejection fraction, larger left ventri-
cles, and larger left atria. There was no difference in the prevalence
of ischaemic aetiology, previous history of myocardial infarction,
atrial fibrillation at baseline, chronic kidney disease, chronic
obstructive pulmonary disease, or use of ACE inhibitors/ARBs or
device therapy, although there was a trend for a reduced use of
beta-blockers in patients with more severe FMR (Table 1).
Functional mitral regurgitation and death
or heart transplantation
After a mean follow-up of 5.1+ 3.5 years, 190 (40.5%) patients
had died (n ¼ 135) or undergone heart transplantation (n ¼ 85).
There was a strong graded association between the presence
and degree of FMR and risk of death or heart transplant (P,
0.0001) (Figure 1). At 5 years, transplant-free survival was 82.7+
3.1% in patients with no or Grade I FMR, 64.4+4.9% in Grade
II, 58.5+ 4.6% in Grade III, and 46.5+6.7% in Grade IV.
Throughout the follow-up, compared with those with no or
Grade I FMR (referent group), patients with Grade II FMR had
an almost 50% increased risk of dying or undergoing heart trans-
plantation (unadjusted HR: 1.47, 95% CI: 0.92–2.34, P ¼ 0.106),
those with Grade III FMR had more than two-fold increased risk
(unadjusted HR: 2.67, 95% CI 1.83–3.91, P, 0.001), and those
with Grade IV FMR had more than three-fold increased risk (unad-
justed HR: 3.59, 95% CI: 2.33–5.54, P, 0.0001); the x2 for the
unadjusted model was 46.48.
Multivariable survival analysis
After adjusting for age, sex, NYHA class, ischaemic aetiology, atrial
fibrillation at baseline, chronic kidney disease, chronic obstructive
pulmonary disease, ACE inhibitors/ARBs, beta-blockers, ICD,
cardiac resynchronization therapy, and LV ejection fraction, wor-
sening degree of FMR remained significantly associated with a pro-
gressively increased risk of death or heart transplantation, P ¼
0.0003 (adjusted HR: 1.32, 95% CI: 0.82–2.13, P ¼ 0.247 for
Grade II FMR; adjusted HR: 2.02, 95% CI: 1.36–3.01, P ¼ 0.0005
for Grade III FMR; and adjusted HR: 2.56, 95% CI: 1.59–4.10,
P ¼ 0.0001 for Grade IV FMR, all compared with no or Grade I
FMR) (Table 2). Other independent predictors of death or heart
transplant were older age, male sex, higher NYHA class, lack of
cardiac resynchronization therapy, and lower LV ejection fraction.
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Table 1 Baseline characteristics according to the degree of functional mitral regurgitation
No FMR and Grade I FMR
(n5 176)
Grade II FMR
(n 5 87)
Grade III FMR
(n 5 142)
Grade IV FMR
(n5 64)
P for
trend
Age (years) 60.5+13.7 58.7+12.0 60.1+14.3 56.9+11.5 0.260
Men 116 (63.9) 56 (64.4) 99 (69.7) 42 (65.6) 0.831
NYHA Class I– II 138 (78.4) 57 (65.5) 90 (63.4) 31 (48.4)
NYHA Class III– IV 38 (21.6) 30 (34.5) 52 (36.5) 33 (51.6) ,0.0001
Ischaemic aetiology 64 (36.4) 37 (42.5) 47 (33.1) 22 (34.4) 0.533
Previous myocardial infarction 54 (30.7) 27 (31.0) 32 (22.5) 17 (26.6) 0.183
Atrial fibrillation 24 (13.6) 14 (16.1) 29 (20.4) 13 (20.3) 0.092
Chronic kidney disease 18 (10.2) 7 (8.0) 18 (12.7) 4 (6.3) 0.841
COPD 22 (12.5) 4 (4.6) 19 (13.4) 12 (18.8) 0.214
Beta-blockers 115 (65.3) 51 (58.6) 78 (54.9) 35 (54.7) 0.048
ACE inhibitors/ARBs 158 (89.8) 74 (85.1) 130 (91.5) 54 (84.4) 0.651
ICD 25 (14.2) 17 (19.5) 26 (18.3) 10 (15.6) 0.541
Cardiac resynchronization therapy 20 (11.4) 9 (10.3) 22 (15.5) 4 (6.3) 0.893
LV ejection fraction (%) 32.3+7.8 29.7+7.9 27.9+7.6 26.1+6.2 ,0.0001
LVEDDa (mm) 65.1+8.3 69.4+8.4 70.3+9.5 71.7+9.8 ,0.0001
LA dimensionb (mm) 43.0+6.8 46.7+7.9 48.8+7.3 51.1+6.7 ,0.0001
Data are presented as n (%) or as mean+ SD.
NYHA, New York Heart Association; COPD, chronic obstructive pulmonary disease; ICD, implantable cardioverter defibrillator; ACE, angiotensin converting enzyme; ARB,
angiotensin receptor blocker; LV, left ventricular; LVEDD, left ventricular end-diastolic dimension; LA, left atrium.
aAvailable in 450 patients.
bAvailable in 343 patients.
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The x2 for the full multivariable model including FMR was 126.26,
the x2 for the multivariable model excluding FMR, but including all
other variables, was 104.02.
Increasing degrees of FMR were associated with progressively
increased risk of death or heart transplant regardless of the aetiol-
ogy of FMR (P-value ¼ 0.732 for the interaction term FMR*ischae-
mic aetiology).
Functional mitral regurgitation and
prognosis by New York heart association
functional class
Worse NYHA class was associated with a significantly increased
risk of death or heart transplantation (unadjusted HR: 1.34, 95%
CI: 1.22–1.47, P, 0.0001 for NYHA Class III– IV compared with
NYHA Class I– II). There was a significant interaction between
FMR and NYHA functional class in predicting death or need for
heart transplant, (P, 0.0001 for the interaction term
FMR*NYHA III– IV). Therefore, we stratified the patients into
two groups: 316 patients with milder CHF severity (NYHA Class
I– II) and 153 patients with advanced CHF symptoms (NYHA
Class III– IV).
Among the 316 patients in NYHA I–II, 97 subjects died or
underwent heart transplantation. In this subgroup, FMR was an
independent predictor of events even after adjusting for age, sex,
aetiology, atrial fibrillation, chronic renal failure, chronic obstruc-
tive pulmonary disease, ACE inhibitors/ARBs, beta-blockers, ICD,
cardiac resynchronization therapy, and LV ejection fraction (P,
0.0001).
Among the 153 patients in NYHA Class III– IV, 93 patients died
or underwent heart transplantation. FMR was no longer a signifi-
cant predictor of events at univariate analysis and after adjusting
for age, sex, aetiology, atrial fibrillation, chronic renal failure,
chronic obstructive pulmonary disease, ACE inhibitors/ARBs, beta-
blockers, ICD, cardiac resynchronization therapy, and LV ejection
fraction. The only independent predictor of worse outcome in
this subgroup was age (P ¼ 0.016).
Functional mitral regurgitation and
prognosis in higher risk patients
We used propensity score analysis to calculate the predicted prob-
ability of death or heart transplant by incorporating the following
variables in a multivariable logistic regression model: age, sex,
NYHA class, aetiology, atrial fibrillation at baseline, chronic renal
failure, chronic obstructive pulmonary disease, ACE inhibitors/
ARB, beta-blockers, ICD, cardiac resynchronization therapy, and
LV ejection fraction. We classified as higher risk the patients in
the highest quartile of distribution of the predicting probability
variable. We subsequently analysed the impact of FMR on
transplant-free survival among patients at higher risk and among
the remainder. Among patients not at higher risk of death or
heart transplant based on this multivariable predicting model,
FMR was associated with a progressively increased risk (P,
0.0001), while among patients at higher risk FMR was no longer
associated with a significantly increased risk of death or heart
transplant. (Table 3).
All analyses were repeated under non-surgical management
(censoring patients alive at the time of coronary bypass or mitral
valve surgery) and the results were similar (Table 4). The present
study was not powered to address cause-specific death;
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Table 2 Multivariable regression model for death or
heart transplant in the entire population
Adjusted
HR
95% CI P
No FMR or Grade I (referent
group)
1
FMR Grade II 1.32 0.82–2.13 0.247
FMR Grade III 2.02 1.36–3.01 0.0005
FMR Grade IV 2.56 1.59–4.10 0.0001
Age 1.02 1.00–1.03 0.019
Men 1.52 1.07–2.15 0.019
NYHA class 1.42 1.12–1.79 0.003
Ischaemic aetiology 1.10 0.80–1.51 0.571
Atrial fibrillation 1.38 0.96–1.98 0.079
Chronic kidney disease 1.32 0.84–2.07 0.229
COPD 0.80 0.51–1.26 0.341
ACE inhibitors/ARBs 0.91 0.57–1.44 0.683
Beta-blockers 0.84 0.62–1.14 0.262
ICD 0.66 0.38–1.15 0.140
Cardiac resynchronization
therapy
0.31 0.14–0.67 0.003
LV ejection fraction (per 10%
increase)
0.74 0.60–0.91 0.003
Abbreviations as in Table 1.
Figure 1 Event-free survival according to the presence and
degree of functional mitral regurgitation. Blue line indicates
patients without functional mitral regurgitation or Grade I func-
tional mitral regurgitation, green line indicates patients with
Grade II functional mitral regurgitation, yellow line indicates
patients with Grade III functional mitral regurgitation, and red
line indicates patients with Grade IV functional mitral
regurgitation.
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however, the distribution of cause of death is reported. Cardiac
death occurred in 71.3% of the cases: 62.9% in patients with no
or Grade I FMR, 79.2% with Grade II, 78.2% with Grade III, and
59.1% with Grade IV; sudden death occurred in 14.3% of patients
with no or Grade I FMR, 12.5% with Grade II, 18.2% with Grade III,
and 13.6% with Grade IV (all P ¼ NS).
Discussion
In a large cohort of patients with CHF and LV systolic dysfunction
managed at dedicated CHF clinics, FMR is common and indepen-
dently associated with increased risk of death and need for heart
transplant. Although this association was strong and independent
in patients with less severe CHF symptoms and in patients at
lower overall risk, FMR did not provide independent prognostic
information in patients with more advanced CHF or in the
higher risk subgroup.
CHF is one of the leading causes of death in western countries.
Several potential therapeutic strategies have been attempted;
however, only a few have provided favourable effects on long-term
survival.17,18 These include beta-blockers, ACE inhibitors or ARBs,
ICDs, and cardiac resynchronization therapy. Clinical management
at a dedicated multidisciplinary clinic is reported to be associated
with a better outcome.9–11 The American Heart Association has
recently underscored the importance of investigating effective
systems to ensure the use of evidence-based, guideline-
recommended therapies for prevention of CHF and promoted be-
havioural research into improving compliance and adherence.19
The advantage of studying prognostic determinants in the setting
of a management programme like ours is that patients are homo-
geneously managed according to up-to-date guidelines by the same
team of physicians. The more consistent use of appropriate CHF
therapies in patients evaluated in the CHF clinic has reduced the
potential bias observed in patients selected from other sources
in which CHF therapies may be less consistently applied.1,5,6
In our CHF population, FMR was detected in a large proportion
of patients (94.7%) by echocardiography. Nearly one in six patients
was found to have severe FMR, and almost half had at least mod-
erate FMR. This prevalence is higher than previously reported1,6,20
and it partly reflects the severity of LV disease in our study popu-
lation, characterized by a low mean LV ejection fraction and large
left ventricles and atria. The degree of FMR correlated with the
severity of LV remodelling and systolic dysfunction, as well as
with the severity of symptoms. However, it is difficult to clarify
the relative contributions of these variables to the pathogenesis
of FMR and CHF. Similarly, there are uncertainties about
whether FMR has a causal role in the progression of LV remodel-
ling.20 Previous experimental data has demonstrated that FMR con-
tributes little to the worsening of LV remodeling;21,22 however,
another study showed that even moderate FMR was directly
involved in the progression of LV remodelling.23 More recently,
Acker et al.24 found that in dilated hearts, mitral valve repair had
effects only in modest LV remodelling. Similarly, Braun et al.25
demonstrated in a cohort of patients with ischaemic mitral regur-
gitation that LV reverse remodelling occurred in the group with an
LV end-diastolic diameter 65 mm, while no benefit was demon-
strated for patients with an LV end-diastolic diameter .65 mm.
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Table 3 Univariate regression analysis for death and
heart transplant in patients in the highest quartile of risk
(higher risk) and in the remainder (not higher risk)
based on a propensity score model
HR 95% CI P
Higher risk patients
No FMR or Grade I (referent
group)
1
FMR Grade II 0.99 0.47–2.06 0.977
FMR Grade III 1.43 0.76–2.67 0.267
FMR Grade IV 1.66 0.83–3.32 0.154
Not higher risk patients
No FMR or Grade I (referent
group)
1
FMR Grade II 1.22 0.65–2.30 0.527
FMR Grade III 2.41 1.47–3.94 0.0004
FMR Grade IV 3.55 2.00–6.30 ,0.0001
. . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . .
Table 4 Univariate andmultivariable regressionmodel
for death or heart transplant under non-surgical
management in the entire population
HR 95% CI P
No FMR or Grade I
(referent group)
1
FMR Grade II 1.44 0.90–2.31 0.131
FMR Grade III 2.69 1.84–3.93 ,0.0001
FMR Grade IV 3.58 2.32–5.52 ,0.0001
Adjusted HR 95% CI P
No FMR or Grade I
(referent group)
1
FMR Grade II 1.28 0.79–2.07 0.313
FMR Grade III 2.04 1.37–3.03 0.0004
FMR Grade IV 2.51 1.56–4.03 0.0001
Age 1.02 1.00–1.03 0.016
Men 1.56 1.10–2.22 0.013
NYHA class 1.44 1.14–1.82 0.002
Ischaemic aetiology 1.05 0.76–1.46 0.759
Atrial fibrillation 1.43 1.00–2.05 0.048
COPD 0.78 0.49–1.23 0.283
Chronic kidney
disease
1.28 0.82–2.02 0.278
ACE inhibitors/ARBs 0.92 0.58–1.46 0.724
Beta-blockers 0.82 0.60–1.11 0.197
ICD 0.68 0.39–1.18 0.170
Cardiac
resynchronization
therapy
0.30 0.14–0.65 0.002
LV ejection fraction
(per 10% increase)
0.74 0.60–0.90 0.003
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These most recent data support the active role of FMR in LV
remodelling and suggest that mitral valve repair may be of potential
benefit in a subgroup of properly selected CHF patients with
regard to the degree of the underlying LV remodelling.26 We
have demonstrated that the presence and degree of FMR was
associated with an almost linear increase in the risk of death or
heart transplant at a mean follow-up of 5 years. Furthermore,
the association between FMR severity and outcome remained
strong even after multivariable adjustments for several potential
confounders such as age, sex, NYHA class, ischaemic vs. non-
ischaemic aetiology, LV ejection fraction, comorbidities, and treat-
ment, including ICD and cardiac resynchronization therapy.
Clinical studies, mainly retrospective subanalyses of trials, have
shown an effect of FMR on outcome27 when considered alone,
but often this association was lost after multivariable adjustment.8
Some investigators have found FMR to hold no predictive power.7
Conversely, other studies have demonstrated the direct and inde-
pendent relationship between FMR severity and mortality.1,28,29
Possible explanations for this discrepancy are that the aforemen-
tioned retrospective studies were heterogeneous for patient man-
agement; they did not systematically exclude patients with organic
mitral regurgitation, most of them included only post-myocardial
infarction patients and they did not distinguish on severity.
To the best of our knowledge, this is the first study to examine
the prognostic role of FMR severity over the whole spectrum of
patients with systolic dysfunction and CHF followed at outpatient
CHF clinics. In this setting, we have demonstrated that FMR was a
strong and independent determinant of prognosis in less severe
CHF, but not in the most advanced functional classes. The distri-
bution of sudden death was similar across FMR categories, thus
it is unlikely that death from arrhythmias could have influenced
the effect of FMR on outcome.
Thus, our results reconcile the apparently discrepant previous
data and concur with the observational study by Patel et al.,8 by
showing that among patients with advanced CHF, FMR is no
longer an independent prognostic marker. Once CHF has
progressed to the more advanced stages the prognosis is poor,
and the clinical predictors that have been observed in unselected
populations or in less severe patients may no longer contribute
to worsening LV remodelling and may no longer impact on prog-
nosis. In order to corroborate these findings, we used propensity
score analysis to identify the patients in the highest quartile of risk
based on clinical characteristics and assessed the role of FMR in
these patients. We found similarly that while in patients at lower
risk the incremental prognostic role of FMR was strong, among
high-risk patients FMR did not add much to prognosis.
Clinical implications
FMR is certainly an appealing target for surgical intervention in
patients managed with contemporary CHF therapy. Mitral valve
repair in these patients is easily accomplished by ring annuloplasty
with an acceptable operative mortality.24
Our data raise concerns that the reduction in FMR severity
would affect survival in patients with advanced CHF less than it
would affect patients in NYHA Class I and II. Many patients with
severely remodelled ventricles, right ventricular dysfunction, and
end organ failure may have missed their therapeutic window.30
Indeed, one might speculate that earlier treatment of FMR
(before progression to advanced CHF) is a more efficient
approach. However, more investigation with appropriately
designed clinical trials is needed before the use of surgical annulo-
plasty or percutaneous mitral annuloplasty can be advocated for
less severe functional FMR or less severe CHF. The present
study provides clues on how to re-interpret the previously, appar-
ently discrepant findings on the prognostic impact of FMR and
suggests which subgroups of patients should be investigated in
future studies.
Limitations
Quantitative FMR measurements were not available for most
patients. However, this is unlikely to have affected the results as,
in functional MR, the regurgitant jet is usually central and correlates
well with the regurgitant volume.14 Furthermore, although the
graded association between FMR and outcomes does not imply
that there is a cause-effect relationship, it strengthens the results
of the present study.
Our study was retrospective and the findings are applicable to
patients with systolic CHF followed at dedicated outpatient
clinics where medical therapy is maximized and optimized in
each single patient case-by-case; therefore, caution should be
used when generalizing these findings to CHF patients in general.
Conclusion
In a large cohort of patients with CHF and LV systolic dysfunction
treated with optimal medical and device treatment, FMR was inde-
pendently associated with increased risk of death and heart trans-
plantation in patients with less severe CHF symptoms and in
patients at lower overall risk. This underscores the complexity of
the relationship between FMR and prognosis among patients
with CHF.
Conflict of interest: none declared.
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